Will a vaccine targeting the Omicron variant be available in the US before April 1, 2022?
Will a vaccine targeting the Omicron variant be available in the US before April 1, 2022?
If a vaccine engineered to specifically provide protection against the Omicron variant of COVID-19, whether or not it additionally protects against other variants of SARS-CoV-2, is released for public use in the US, regardless of whether its use is restricted to particular population segments, before April 1, 2022, 12:00:00 AM ET, this market will resolve to “Yes.” Otherwise this market will resolve to “No”.
The source used to resolve this market will be official information released by the FDA (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization) and/or other official information from the government of the United States of America.
Note, this market is only for a vaccine’s availability in the United States, and does not cover any vaccine’s availability in any other country.
If a vaccine engineered to specifically provide protection against the Omicron variant of COVID-19, whether or not it additionally protects against other variants of SARS-CoV-2, is released for public use in the US, regardless of whether its use is restricted to particular population segments, before April 1, 2022, 12:00:00 AM ET, this market will resolve to “Yes.” Otherwise this market will resolve to “No”.
The source used to resolve this market will be official information released by the FDA (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization) and/or other official information from the government of the United States of America.
Note, this market is only for a vaccine’s availability in the United States, and does not cover any vaccine’s availability in any other country.If a vaccine engineered to specifically provide protection against the Omicron variant of COVID-19, whether or not it additionally protects against other variants of SARS-CoV-2, is released for public use in the US, regardless of whether its use is restricted to particular population segments, before April 1, 2022, 12:00:00 AM ET, this market will resolve to “Yes.” Otherwise this market will resolve to “No”.
The source used to resolve this market will be official information released by the FDA (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization) and/or other official information from the government of the United States of America.
Note, this market is only for a vaccine’s availability in the United States, and does not cover any vaccine’s availability in any other country.
The source used to resolve this market will be official information released by the FDA (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization) and/or other official information from the government of the United States of America.
Note, this market is only for a vaccine’s availability in the United States, and does not cover any vaccine’s availability in any other country.
市场开放时间： Jan 24, 2022, 7:00 PM ET
交易量
$29,057结束日期
Apr 1, 2022市场开放时间
Jan 24, 2022, 7:00 PM ET已提议结果: No
无争议
最终结果: No
If a vaccine engineered to specifically provide protection against the Omicron variant of COVID-19, whether or not it additionally protects against other variants of SARS-CoV-2, is released for public use in the US, regardless of whether its use is restricted to particular population segments, before April 1, 2022, 12:00:00 AM ET, this market will resolve to “Yes.” Otherwise this market will resolve to “No”.
The source used to resolve this market will be official information released by the FDA (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization) and/or other official information from the government of the United States of America.
Note, this market is only for a vaccine’s availability in the United States, and does not cover any vaccine’s availability in any other country.
If a vaccine engineered to specifically provide protection against the Omicron variant of COVID-19, whether or not it additionally protects against other variants of SARS-CoV-2, is released for public use in the US, regardless of whether its use is restricted to particular population segments, before April 1, 2022, 12:00:00 AM ET, this market will resolve to “Yes.” Otherwise this market will resolve to “No”.
The source used to resolve this market will be official information released by the FDA (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization) and/or other official information from the government of the United States of America.
Note, this market is only for a vaccine’s availability in the United States, and does not cover any vaccine’s availability in any other country.If a vaccine engineered to specifically provide protection against the Omicron variant of COVID-19, whether or not it additionally protects against other variants of SARS-CoV-2, is released for public use in the US, regardless of whether its use is restricted to particular population segments, before April 1, 2022, 12:00:00 AM ET, this market will resolve to “Yes.” Otherwise this market will resolve to “No”.
The source used to resolve this market will be official information released by the FDA (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization) and/or other official information from the government of the United States of America.
Note, this market is only for a vaccine’s availability in the United States, and does not cover any vaccine’s availability in any other country.
The source used to resolve this market will be official information released by the FDA (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization) and/or other official information from the government of the United States of America.
Note, this market is only for a vaccine’s availability in the United States, and does not cover any vaccine’s availability in any other country.
交易量
$29,057结束日期
Apr 1, 2022市场开放时间
Jan 24, 2022, 7:00 PM ET已提议结果: No
无争议
最终结果: No
警惕外部链接哦。
警惕外部链接哦。
常见问题